For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …

Early stage developability assessments of monoclonal antibody (mAb) candidates can help
reduce risks and costs associated with their product development. Forecasting viscosity of …

The ability of antibodies to recognize their target antigens with high specificity is
fundamental to their natural function. Nevertheless, therapeutic antibodies display variable …

Purpose Early identification of monoclonal antibody candidates whose development, as
high concentration (≥ 100 mg/mL) drug products, could prove challenging, due to high …

Antibodies are used extensively in diagnostics and as therapeutic agents. Achieving high-
affinity binding is important for expanding detection limits, extending dissociation half-times …

Undesired solution behaviors such as reversible self-association (RSA), high viscosity, and
liquid-liquid phase separation can introduce substantial challenges during development of …

Biologics, such as antibodies and enzymes, are crucial in research, biotechnology,
diagnostics, and therapeutics. Often, biologics with suitable functionality are discovered, but …

In recent years, computational methods have garnered much attention in protein
engineering. A large number of computational methods have been developed to analyze the …

Highlights•Specificity is a critical attribute of drug-like monoclonal antibodies.•Antibody
specificity is compromised by excess localized charge and/or hydrophobicity.•High …

Therapeutic proteins such as antibodies constitute the most rapidly growing class of
pharmaceuticals for use in diverse clinical settings including cancer, chronic inflammatory …